Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: Neurocrine is a biopharmaceutical company focused on discovering and developing drugs for neurological and endocrine-related diseases. The company has no approved commercial products and generates revenue primarily through collaboration agreements. Its lead clinical candidate is indiplon, a non-benzodiazepine for the treatment of insomnia.
Key Financial Metrics
| Metric (in thousands) | 2006 | 2005 |
|---|---|---|
| Total Revenues | $39,234 | $123,889 |
| Net Loss | $(107,205) | $(22,191) |
| Loss Per Share (Basic/Diluted) | $(2.84) | $(0.60) |
| Research & Development Expenses | $97,678 | $106,628 |
| Sales, General & Administrative Expenses | $54,873 | $42,333 |
| Cash, Cash Equivalents & Short-Term Investments | $182,604 | $273,068 |
| Long-Term Debt | $49,152 | $53,590 |
| Accumulated Deficit | $(407,351) | $(300,146) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 68% to $39.2 million from $123.9 million in 2005. This was primarily due to the absence of a $70.0 million milestone payment received from Pfizer in 2005 related to the FDA acceptance of indiplon NDAs.
- Increased Net Loss: Net loss widened significantly to $107.2 million from $22.2 million. Contributing factors included the loss of Pfizer milestone revenue, a one-time restructuring charge of $9.5 million, and the adoption of SFAS 123R (share-based compensation) which added $14.6 million in non-cash expense.
- Collaboration Termination: On June 22, 2006, Neurocrine terminated its exclusive collaboration with Pfizer regarding indiplon, effective December 19, 2006. Neurocrine reacquired all worldwide rights and assumed full responsibility for development and commercialization costs.
- Restructuring: The company eliminated its entire 200-person sales force and reduced R&D and G&A staff by approximately 100 employees in 2006 to reduce future operating expenses.
Guidance, Outlook, and Risks
- Indiplon Regulatory Status:
- Capsules: FDA issued an "Approvable" letter for 5mg and 10mg capsules. Neurocrine is resubmitting the NDA, targeted for the end of Q2 2007.
- Tablets: FDA issued a "Not Approvable" letter for 15mg tablets due to insufficient sleep maintenance data. Additional long-term safety and efficacy data are required.
- Liquidity Outlook: Management expects to use approximately $80.0 million in cash during 2007 and anticipates ending the year with at least $100.0 million in cash. Existing resources are deemed sufficient for the next 12 months.
- Key Risks:
- Failure to obtain FDA approval for indiplon or delays in the resubmission process.
- Inability to secure a new commercialization partner for indiplon on favorable terms.
- Potential impairment of the $94.0 million prepaid royalty asset if indiplon commercialization is delayed or fails.
- Continued operating losses and negative cash flow until product approval.
Investor Verification Checklist
- Indiplon NDA Resubmission: Verify the timeline and content of the NDA resubmission for indiplon capsules targeted for Q2 2007.
- Partnership Strategy: Confirm progress in identifying a new commercial partner for indiplon following the Pfizer termination.
- Asset Impairment: Monitor the quarterly assessment of the $94.0 million prepaid royalty asset for potential impairment charges.
- Cash Burn Rate: Track actual cash usage against the projected $80.0 million burn rate for 2007.
- Tablet Program: Review the strategy and data requirements for the indiplon tablet formulation, which currently lacks FDA approval.